ATE516016T1 - Selbstemulgierende formulierungen von cetp- hemmern - Google Patents
Selbstemulgierende formulierungen von cetp- hemmernInfo
- Publication number
- ATE516016T1 ATE516016T1 AT06839075T AT06839075T ATE516016T1 AT E516016 T1 ATE516016 T1 AT E516016T1 AT 06839075 T AT06839075 T AT 06839075T AT 06839075 T AT06839075 T AT 06839075T AT E516016 T1 ATE516016 T1 AT E516016T1
- Authority
- AT
- Austria
- Prior art keywords
- self
- cetp inhibitors
- emulsifying formulations
- cetp inhibitor
- formulations
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74245105P | 2005-12-05 | 2005-12-05 | |
| PCT/US2006/046503 WO2007067593A2 (en) | 2005-12-05 | 2006-12-05 | Self-emulsifyng formulations of cetp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516016T1 true ATE516016T1 (de) | 2011-07-15 |
Family
ID=38123443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06839075T ATE516016T1 (de) | 2005-12-05 | 2006-12-05 | Selbstemulgierende formulierungen von cetp- hemmern |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8486983B2 (de) |
| EP (1) | EP1965764B1 (de) |
| AT (1) | ATE516016T1 (de) |
| WO (1) | WO2007067593A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2635010A1 (en) * | 2005-12-30 | 2007-07-19 | Amjad Ali | Oxazolidinone derivatives as cetp inhibitors |
| WO2007092642A2 (en) * | 2006-02-09 | 2007-08-16 | Merck & Co., Inc. | Polymer formulations of cetp inhibitors |
| WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
| CN102015606B (zh) | 2007-06-08 | 2015-02-04 | 满康德股份有限公司 | IRE-1α抑制剂 |
| JP2011506541A (ja) * | 2007-12-17 | 2011-03-03 | ノバルティス アーゲー | カルボキシルエステラーゼ１調節を介した高密度リポタンパク質レベルの変換 |
| JP2013527148A (ja) * | 2010-04-07 | 2013-06-27 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｃｅｔｐ発現の調節 |
| US20120095098A1 (en) * | 2010-10-18 | 2012-04-19 | Bhiku Patel | Bioavailability Enhancement Delivery System |
| WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| WO2014099836A1 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
| EP2934519B1 (de) | 2012-12-20 | 2021-05-12 | Merck Sharp & Dohme Corp. | Therapeutische thiazolidinonverbindungen |
| US9981970B2 (en) | 2013-07-30 | 2018-05-29 | Merck Sharp & Dohme Corp. | Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors |
| EP3054945B1 (de) | 2013-10-10 | 2018-08-15 | Merck Sharp & Dohme Corp. | 3,3'-disubstituierte indoline als hemmer des cholesterinestertransferproteins |
| WO2015094932A1 (en) | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| EP3174537B1 (de) | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclische isoxazoline als hemmer des cholesterinestertransferproteins |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| CN113616614A (zh) * | 2021-07-22 | 2021-11-09 | 浙江和泽医药科技股份有限公司 | 一种醋酸阿比特龙软胶囊及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992021348A1 (en) | 1991-06-03 | 1992-12-10 | Merck Sharp & Dohme Limited | Pharmaceutical formulations of a benzodiazepine |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| PL368850A1 (en) * | 2001-06-21 | 2005-04-04 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| EP1269994A3 (de) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten |
| KR20060033033A (ko) * | 2003-08-04 | 2006-04-18 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형 |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| CA2612142A1 (en) | 2005-07-01 | 2007-01-11 | Merck & Co., Inc. | Process for synthesizing a cetp inhibitor |
-
2006
- 2006-12-05 EP EP06839075A patent/EP1965764B1/de not_active Not-in-force
- 2006-12-05 WO PCT/US2006/046503 patent/WO2007067593A2/en not_active Ceased
- 2006-12-05 US US12/085,745 patent/US8486983B2/en active Active
- 2006-12-05 AT AT06839075T patent/ATE516016T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1965764B1 (de) | 2011-07-13 |
| EP1965764A2 (de) | 2008-09-10 |
| WO2007067593A2 (en) | 2007-06-14 |
| US8486983B2 (en) | 2013-07-16 |
| WO2007067593A3 (en) | 2007-10-25 |
| US20090186926A1 (en) | 2009-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516016T1 (de) | Selbstemulgierende formulierungen von cetp- hemmern | |
| WO2003105800A3 (de) | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen | |
| TW200517106A (en) | Sustained release pharmaceutical compositions | |
| DE602005014382D1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren | |
| ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| WO2006035417A3 (en) | Dihydropyrimidine microcapsule - formulations | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| NO20072058L (no) | Inhibitorer av interaksjonen mellom MDM2 og P53 | |
| NO20033732L (no) | N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser. | |
| DK2046292T3 (da) | Formuleringer for benzimidazolylpyridylethere | |
| WO2004063151A3 (en) | Novel tyrosine kinase inhibitors | |
| WO2003105767A3 (en) | Antifungal parenteral products | |
| DK0989851T3 (da) | Selvemulgerende formulering indeholdende sure lipofile forbindelser | |
| EP1619180A4 (de) | Casr-antagonist | |
| BR0212386A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| WO2004100865A3 (en) | New benzimidazole derivatives | |
| SE0000774D0 (sv) | New formulation | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| CL2022000040A1 (es) | Composición farmacéutica que comprende un compuesto de tetrahidropirazolopirimidinona | |
| EP1993567A4 (de) | Oral verabreichbare gallium-zusammensetzungen und anwendungsverfahren | |
| EA201101119A1 (ru) | Дозируемая форма, содержащая пантопразол в качестве активного ингредиента | |
| MY138172A (en) | Pharmaceutical compositions based on azetidine derivatives | |
| EA200601015A1 (ru) | Пероральные композиции дезоксипеганина и их применение | |
| AR046719A1 (es) | Sales de benzazepina y composiciones farmacéuticas que las contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |